Skip to Content

Retreatment with venetoclax + anti-CD20 monoclonal antibody for patients with relapsed/refractory CLL

This MEDtalk adresses the first prospective clinical trial to evaluate the efficacy and safety of retreatment with venetoclax in combination with obinutuzumab. This treatment is initialized at the time of progressive disease in patients who had initially responded to 1L venetoclax- obinutuzumab for at least 12 months after completing therapy. The results are presented by Matthew S. Davids, MD, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.

Matthew S. Davids

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top